Medicus Pharma (MDPLD) | Financial Analysis & Statements
Medicus Pharma Ltd. Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2024Income Metrics
Revenue
0
Operating Income
-3.0M
Net Income
-3.0M
EPS (Diluted)
$-0.62
Balance Sheet Metrics
Total Assets
5.7M
Total Liabilities
2.2M
Shareholders Equity
3.5M
Debt to Equity
0.64
Cash Flow Metrics
Operating Cash Flow
-2.9M
Free Cash Flow
-3.1M
Revenue & Profitability Trend
Medicus Pharma Income Statement From 2023 to 2023
| Metric | 2023 |
|---|---|
| Revenue | 0 |
| Cost of Goods Sold | - |
| Gross Profit | - |
| Gross Margin % | 0.0% |
| Operating Expenses | |
| Research & Development | 193.6K |
| Selling, General & Administrative | 2.8M |
| Other Operating Expenses | - |
| Total Operating Expenses | 3.0M |
| Operating Income | -3.0M |
| Operating Margin % | 0.0% |
| Non-Operating Items | |
| Interest Income | - |
| Interest Expense | 739.1K |
| Other Non-Operating Income | -2.6M |
| Pre-tax Income | -6.8M |
| Income Tax | - |
| Effective Tax Rate % | 0.0% |
| Net Income | -6.8M |
| Net Margin % | 0.0% |
| Key Metrics | |
| EBITDA | -6.7M |
| EPS (Basic) | $-1.94 |
| EPS (Diluted) | $-1.94 |
| Basic Shares Outstanding | 3479509 |
| Diluted Shares Outstanding | 3479509 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Medicus Pharma Balance Sheet From 2021 to 2023
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Assets | |||
| Current Assets | |||
| Cash & Equivalents | 1.7M | 267.7K | 78.5K |
| Short-term Investments | - | - | - |
| Accounts Receivable | - | - | - |
| Inventory | - | - | - |
| Other Current Assets | - | - | - |
| Total Current Assets | 1.9M | 282.7K | 78.5K |
| Non-Current Assets | |||
| Property, Plant & Equipment | - | - | - |
| Goodwill | - | - | - |
| Intangible Assets | - | - | - |
| Long-term Investments | - | - | - |
| Other Non-Current Assets | - | - | - |
| Total Non-Current Assets | 0 | 0 | 0 |
| Total Assets | 1.9M | 282.7K | 78.5K |
| Liabilities | |||
| Current Liabilities | |||
| Accounts Payable | - | - | - |
| Short-term Debt | - | 1.5M | 667.9K |
| Current Portion of Long-term Debt | - | - | - |
| Other Current Liabilities | - | 10.8M | 9.8M |
| Total Current Liabilities | 1.1M | 12.5M | 10.6M |
| Non-Current Liabilities | |||
| Long-term Debt | - | - | - |
| Deferred Tax Liabilities | - | - | - |
| Other Non-Current Liabilities | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 |
| Total Liabilities | 1.1M | 12.5M | 10.6M |
| Equity | |||
| Common Stock | 19.8M | 194.5K | 194.5K |
| Retained Earnings | -19.2M | -12.4M | -10.7M |
| Treasury Stock | - | - | - |
| Other Equity | - | - | - |
| Total Shareholders Equity | 805.8K | -12.2M | -10.5M |
| Key Metrics | |||
| Total Debt | 0 | 1.5M | 667.9K |
| Working Capital | 805.8K | -12.2M | -10.5M |
Balance Sheet Composition
Medicus Pharma Cash Flow Statement From 2023 to 2023
| Metric | 2023 |
|---|---|
| Operating Activities | |
| Net Income | -6.8M |
| Depreciation & Amortization | - |
| Stock-Based Compensation | 146.7K |
| Working Capital Changes | 0 |
| Operating Cash Flow | -5.0M |
| Investing Activities | |
| Capital Expenditures | - |
| Acquisitions | - |
| Investment Purchases | - |
| Investment Sales | - |
| Investing Cash Flow | - |
| Financing Activities | |
| Share Repurchases | - |
| Dividends Paid | - |
| Debt Issuance | 500.0K |
| Debt Repayment | - |
| Financing Cash Flow | 5.6M |
| Free Cash Flow | -4.2M |
| Net Change in Cash | 622.9K |
Cash Flow Trend
Medicus Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.47
Price to Book
3.90
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-841.91%
Return on Assets
-358.37%
Financial Health
Current Ratio
2.73
Debt to Equity
0.10
Per Share Data
EPS (TTM)
$-2.54
Book Value per Share
$0.73
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MDPLD | 22.5M | -1.47 | 3.90 | -841.91% | 0.00% | 0.10 |
| Eli Lilly and | 821.3B | 40.09 | 31.01 | 101.16% | 31.67% | 165.31 |
| Johnson & Johnson | 555.8B | 20.49 | 6.68 | 32.87% | 21.83% | 60.50 |
| AbbVie | 351.5B | 83.46 | -108.79 | 6,225.00% | 6.91% | -21.19 |
| Merck & Co | 283.1B | 15.74 | 5.39 | 36.88% | 28.08% | 95.96 |
| Amgen | 187.9B | 24.22 | 21.46 | 106.10% | 20.98% | 640.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.